Clinical trials: Trop2
NSCLC, EGFR Activating Mutation
Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC
The primary objective is to evaluate the correlation between ⁶⁸Ga-MY6349 PET/CT-derived metrics reflecting tumoral TROP2 expression activity (including SUVmax, SUVmean, MTV, TLG, etc.) and progression-free survival (PFS) assessed…
- Conditions
- NSCLC, EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, Trop2
- Trial name
- NCT07685197
- Testing
- receive treatment with TROP2-targeted ADC and targeted molecular PET/CT imaging using ⁶⁸Ga-MY6349 injection
- Volunteers
- 100 people
- Sponsor
- Zhou Chengzhi
HER2 Positive OR TROP2 Positive Non-Small Cell Lung Cancer
Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids
A case-control study was conducted to evaluate the efficacy and mechanism of action of antibody-drug conjugates (ADCs) in lung cancer, utilizing patient-derived organoid (PDO)-immune co-cultures.
- Trial name
- NCT07610616
- Testing
- Antibody-drug conjugate (ADC) combination therapy
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Advanced Solid Tumors, Metastatic Solid Tumors
Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors
study evaluates EB-NK-301, an investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2, in adults with advanced or metastatic solid tumors that express TROP2 and have progressed after standard therapy.
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
- Trial name
- SOLID-NK (NCT07589530)
- Testing
- EB-NK-301, Fludarabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Biotech
PTC, I-131
The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma
Clinincal data and pathological specimens from patients who had undergone at least one radioactive iodine-131 (^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were…
- Conditions
- PTC, I-131, Trop2
- Trial name
- ZL2025 (NCT07314255)
- Testing
- radioiodine-131 therapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangxi Provincial Cancer Hospital
Breast Cancer, Brain Metastases From Breast Cancer
Evaluation of Trop-2 ADC in Breast Cancer Patients With Brain Metastases: A Real-World Study
The goal of this real-world study (RWS) is to evaluate the effectiveness of Trop-2 ADC (sacituzumab govitecan) in treating breast cancer patients with brain metastases, and to understand the safety profile of this drug in real…
- Conditions
- Breast Cancer, Brain Metastases From Breast Cancer, Trop2
- Trial name
- NCT07251868
- Testing
- Sacituzumab Govitecan (SG)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Cancer Hospital & Institute
NSCLC, Trop2
PET/CT for Trop2 ADC Response Evaluation NSCLC
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in NSCLC patients.
- Conditions
- NSCLC, Trop2, PET/CT
- Trial name
- NCT07151898
- Testing
- 68Ga-MY6349 PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Breast Cancer, Trop2
PET/CT for Trop2 ADC Response Evaluation Cancers
To evaluate whether serial 68Ga-MY6349 PET/CT imaging can serve as a noninvasive biomarker to predict the therapeutic efficacy of Trop2-targeted antibody-drug conjugate (Trop2-ADC) therapy in breast cancer patients.
- Conditions
- Breast Cancer, Trop2, PET/CT
- Trial name
- NCT07046689
- Testing
- 68Ga-MY6349 PET/CT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Solid Tumor, Trop2
68Ga-MY6349 PET/CT in Solid Tumors
The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET/CT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET/CT.
- Conditions
- Solid Tumor, Trop2, PET/CT
- Trial name
- NCT07046702
- Testing
- 68Ga-MY6349
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital of Xiamen University